Shwachman Diamond Syndrome – Definition

Shwachman Diamond Syndrome (OMIM #260400) is the second most common cause of exocrine pancreatic insufficiency in children after cystic fibrosis. The disease is associated with bone marrow failure and an increased risk of malignant diseases of the hematopoietic system. Clinically, patients often present with skeletal malformations and short stature.

Synonyms:

SDS, Shwachman-Bodian-Diamond syndrome, congenital pancreatic lipomatosis

Gene:

DNAJC21, EFL1, SBDS, SRP54

Gene ­product:

ATP-dependent DNA helicase DDX11

Function:

Cohesion of sister chromatids and DNA replication, tumor suppressor

Pattern of inheritance:

in most cases autosomal recessive (DNAJC21, EFL1, or SBDS), autosomal dominant (SRP54), de novo

Prevalence:

1: 77.000

Genotype-phenotype correlation:

Unknown

Penetrance:

Unknown

Overview of the Chapters on This Page:

  • Clinical Presentation

  • Special Features of Treatment

  • Recommendations for Early Detection in Your Patients
  • Further Information (e.g., Links to Support Groups)

  • Clinical Presentation

  • Special Features of Treatment

  • Recommendations for Early Detection in Your Patients
  • Further Information (e.g., Links to Support Groups)

Shwachman Diamond Syndrome – Diagnosis

  • Clinical presentation with exocrine pancreal insufficiency and bone marrow failure
    and/or
  • Biallelic variants in the DNAJC21, EFL1, or SBDS gene or heterozygous variant in the SRP54 gene(at least likely pathogenic or pathogenic)

Differential Diagnoses

  • Zystische Fibrose
  • Johanson-Blizzard Syndrom
  • Pearson Syndrom
  • SPINK1-related severe infantile isolated exocrine pancreatic insufficiency
  • Diamond-Blackfan Anämie
  • Fanconi Anämie
  • Dyskeratosis congenita
  • Kostmann-Syndrom
  • ELANE-related neutropenia
  • Knorpel-Haar Hypoplasie

Clinical Presentation

Clinical Anomalies

  • Exocrine pancreatic insufficiency with reduced pancreatic enzymes, reduced elastase-1 in the stool, deficiency of fat-soluble vitamins
  • Neutropenia, anemia, thrombocytopenia up to pancytopenia
  • Short stature, skeletal anomalies (e.g., chondrodysplasia, thoracic deformities)
  • Hepatomegaly, sometimes with elevated liver values
  • Congenital malformations of the heart or ears

Tumor Predisposition

  • Malignant diseases of the hematopoietic system (leukemias, bone marrow hypocellularity or failure)

Special Features of Treatment

  • The prolonged administration of cytokines or growth factors such as G-CSF must be carefully considered, as transformation into leukemic cells cannot be ruled out
  • There is no standard chemotherapeutic treatment regimen for diseases. In the case of leukemia or bone marrow failure, the only curative therapy is stem cell transplantation

Diagnosis of Shwachman Diamond Syndrome- What's Next?

Once diagnosed, it is recommended that a cancer predisposition specialist manage the patient. The following section explains whether cancer screening tests or other measures are necessary and how they should be performed. Some additional information, including links to support groups, is also included at the end of this page.

Diagnosis of Shwachman Diamond Syndrome- What's Next?

Once diagnosed, it is recommended that a cancer predisposition specialist manage the patient. The following section explains whether cancer screening tests or other measures are necessary and how they should be performed. Some additional information, including links to support groups, is also included at the end of this page.

Recommendations for Early Detection in Your Patients

To date, there are no standardized screening recommendations for patients with SDS. Based on the currently available literature, the following is suggested:

  • Differential blood count every 3-6 months, shorter interval if necessary in the case of infections or changes in the cell series
  • Bone marrow punctures every 1-3 years, shorter intervals if necessary in case of abnormalities
  • Checking the nutritional situation every 6 months
  • Checking the vitamin balance every 6 months to monitor pancreatic enzyme therapy
  • During the fastest growth phases, orthopedic checks and, if necessary, X-ray checks of the knee and hip
  • Bone densitometry before, during, and after puberty
  • Developmental monitoring up to 6 years of age, then semi-annual checks on length of growth
  • Neuropsychological screening at the ages of 6-8, 11-13, and 15-17 years

Shwachman Diamond Syndrome – Further Information

Open Clinical Trials/ Registries

Additional Resources

Unfortunately, we are currently not aware of any support groups for patients with Shwachman Diamond syndrome. New information will be added as soon as it becomes available.